AstraZeneca’s kidney blitz

Restricted access

AstraZeneca (Cambridge, UK) is emphasizing its dedication to chronic kidney disease (CKD) and related conditions. In a sign of its focus on the “R” in its renamed division, Cardiovascular, Renal, and Metabolism (CVRM), the company offered research and information in 35 separate scientific articles and data presentations during Kidney Week 2018.

Formerly known as CVMD (cardiovascular, renal, and metabolic diseases), the division was renamed in early 2018. Renal work has become an urgent area of concern, said Elisabeth Bjork, vice president of CVRM for Global Medicines Development. “Deaths due to CKD specifically more than doubled between 1990 and 2013,” she

Save